SCHEMBL1684787

SCHEMBL1684787

Cc1ccc(N(C)c2nccc(-c3c(C)nc4ncccn34)n2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.51
▸ MAPT P10636 7/20 0.51
▸ GAA P10253 7/20 0.51
▸ KDM4E B2RXH2 6/20 0.51
▸ RAB9A P51151 3/20 0.51
▸ LMNA P02545 3/20 0.51
▸ HPGD P15428 2/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ CYP2D6 P10635 1/20 0.51
▸ ALOX12 P18054 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ L3MBTL1 Q9Y468 2/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ DYRK1A Q13627 2/20 0.45
▸ MAPK1 P28482 3/20 0.44
▸ HTT P42858 2/20 0.44
▸ KMT2A Q03164 5/20 0.43
▸ MEN1 O00255 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1684880 0.91 MAPT (0.48) ALDH1A1MAPTGAAKDM4ERAB9A
SCHEMBL1684823 0.89 ALDH1A1 (0.53) ALDH1A1MAPTGAAKDM4ERAB9A
SCHEMBL1684741 0.83 CDK2 (0.60) ALDH1A1MAPTGAAKDM4ELMNA
SCHEMBL1684765 0.81 MAPT (0.44) ALDH1A1MAPTGAAKDM4ERAB9A
SCHEMBL2355015 0.76 CDK2 (0.60) ALDH1A1MAPTGAAKDM4ERAB9A
SCHEMBL1684656 0.76 MAPT (0.65) ALDH1A1MAPTGAAKDM4ERAB9A
SCHEMBL1684609 0.75 MAPT (0.67) ALDH1A1MAPTGAAKDM4ERAB9A
SCHEMBL14054033 0.75 ALDH1A1 (0.56) ALDH1A1MAPTGAAKDM4ERAB9A
SCHEMBL1684891 0.74 CDK2 (0.58) ALDH1A1MAPTGAAKDM4ELMNA
SCHEMBL1684647 0.73 CDK2 (0.56) ALDH1A1MAPTGAAKDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 — — EP claimed
US-8680113-B2 BMI-1 protein expression modulators PTC THERAPEUTICS, INC. (US) 2014-03-25 — — US claimed
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2011-08-04 — — US claimed
EP-2306836-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2011-04-13 — — EP claimed
WO-2010002985-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2010-01-07 — — WO claimed
EP-3111956-B1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2019-05-08 — — EP disclosed
EP-3111956-A1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2017-01-04 — — EP disclosed
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS BMI1, CREBBP, BAZ2A ALDH1A1 2357/4885MAPT 4026/4885GAA 3522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback